ISSN: 1859 - 2872
An analysis of meropenem administration status in the treatment of central nervous system infection at 108 Military Central Hospital
Main Article Content
Keywords
Abstract
Objective: Meropenem is an important antibiotic in the treatment of central nervous system infection, especially with the increase of the multi-drug resistant Gram negative bacteria rate. Therefore, this research was conducted to analyze meropenem administration status in patients diagnosed with central nervous system infection, treated by meropenem at 108 Military Central Hospital in 2023.
Subject and method: Research was conducted as a cross-sectional retrospective study description, according to data from medical records of the patients who were diagnosed with central nervous system infection, treated by meropenem at 108 Military Central Hospital from 1 January to 31 December, 2023. The rationality of meropenem indication and dose was assessed with Vietnamese and international guidelines for treating central nervous system infection, Vietnam National Formulary and the Summary Product Characteristics. Result: There were 47 patients diagnosed with central nervous system infection and treated by meropenem in our research. The most common etiology was Gram-negative bacteria. There were 18 medical records used the non-meropenem initial therapies, others 29 medical records used meropenem as an initiation. Only 3 monotherapies of meropenem, the others were combination. The percentage of rationality of meropenem administration as the initial, alternative, and targeted antibiotic were 55.2%, 75.0%, and 50.0%, respectively. There were 32/45 (71.1%) patients had the appropriate dose according to recommendation. There was 100% of the patients with intravenous infusion and 83% of them with 3-hour extended infusion. Conclusion: The rationality in terms of both indication and dose in hospital prescriptions was relatively good; however, it remained a certain rate that did not align with recommendations. Therefore, it is necessary for clinical pharmacists to participate in reviewing and optimizing meropenem administration in these sensitive patients.
Article Details
References
2. Bộ Y tế (2022), Meropenem, Dược thư Quốc gia
Việt Nam, Nhà xuất bản Y học, tr. 950-952.
3. Edwards JR (1995) Meropenem: a microbiological overview. Journal of Antimicrobial Chemotherapy. 36(suppl_A): 1-17.
4. Bộ Y tế (2020) Hướng dẫn thực hiện quản lý sử dụng kháng sinh trong bệnh viện (Ban hành kèm theo Quyết định số 5631 ngày 31 tháng 12 năm 2020), Nhà xuất bản Y học.
5. Bộ Y tế (2015) Viêm màng não mủ, Hướng dẫn sử dụng kháng sinh, (Ban hành kèm theo Quyết định số 708/QĐ-BYT ngày 02/3/2015), Nhà xuất bản
Y học, tr. 229-233.
6. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, Hartman BJ, Kaplan SL, Scheld WM, Whitley RJ; Infectious Diseases Society of America (2008) The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 47(3):303-327. doi: 10.1086/589747.
7. van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, Leib SL, Mourvillier B, Ostergaard C, Pagliano P, Pfister HW, Read RC, Sipahi OR, Brouwer MC; ESCMID Study Group for Infections of the Brain (ESGIB) (2016) ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 22 Suppl 3:S37-62. doi: 10.1016/j.cmi.2016.01.007.
8. Carter E, McGill F (2022) The management of acute meningitis: An update. Clin Med (Lond) 22(5):396-400. doi: 10.7861/clinmed.2022-cme-meningitis.
9. Bodilsen J, D'Alessandris QG, Humphreys H, Iro MA, Klein M, Last K, Montesinos IL, Pagliano P, Sipahi OR, San-Juan R, Tattevin P, Thurnher M, de J Treviño-Rangel R, Brouwer MC; ESCMID Study Group for Infections of the Brain (ESGIB) (2023) European society of Clinical Microbiology and Infectious Diseases guidelines on diagnosis and treatment of brain abscess in children and adults. Clin Microbiol Infect 30(1):66-89. doi: 10.1016/j.cmi.2023.08.016.
10. Novielli KD, Arenson CA (2003) Overview of geriatrics. Clin Podiatr Med Surg 20(3): 373-381.
11. Oliveira J, Reygaert WC (2023) Gram-Negative Bacteria. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
12. Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008) Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 68(6):803-838. doi: 10.2165/00003495-200868060-00006.
13. Brunton LL, Lazo JS, and Parker KL (2006) Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition, The McGraw Hill Companies.
14. Betram GK and Anthony JT (2015) Basic & Clinical Pharmacology, Thirteenth Edition, McGraw Hill Education.
15. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R (2014) Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect Dis 14(8): 750.
16. Tamma PD, Cosgrove SE, and Maragakis LL (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 25(3): 450-470.
17. Goneau LW, Delport J, Langlois L, Poutanen SM, Razvi H, Reid G, Burton JP (2020) Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence. FEMS Microbes 1(1):xtaa004. doi: 10.1093/femsmc/xtaa004.
18. Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H (2017) Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Pediatr Infect Dis J 36(4):358-363. doi: 10.1097/INF.0000000000001445.
19. Lu C, Zhang Y, Chen M, Zhong P, Chen Y, Yu J, Wu X, Wu J, Zhang J (2016) Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery. Antimicrob Agents Chemother 60(11): 6619-6625. doi: 10.1128/AAC.00997-16.
Article Sidebar
